Rob C Roovers

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 3

Top Topics

Acute Lymphoblastic Leukemia

Dendritic Cells

Immune Response

Top Venues

Cancer immunology research

Expert opinion on biological therapy

LAVA Therapeutics

This page only lists publications with an associated author ORCID identifier.

Affiliation History

LAVA Therapeutics Nov 01 2018

Netherlands

Sr. Dir. Preclinical Development

Universiteit Utrecht Faculteit Bètawetenschappen

Netherlands

Senior Post-Doc :: Cell Biology

Publications

Lisa A King, Elisa C Toffoli, Myrthe Veth, Victoria Iglesias-Guimarais, Manon C Slot, Derk Amsen, Rieneke van de Ven, Sarah Derks, Marieke F Fransen, Jurriaan B Tuynman, Thilo Riedl, Rob C Roovers, Anton E P Adang, Jurjen M Ruben, Paul W H I Parren, Tanja D de Gruijl, Hans J van der Vliet
A bispecific γδ T-cell engager targeting EGFR activates a potent Vγ9Vδ2 T cell-mediated immune response against EGFR-expressing tumors. Cancer immunology research (2023)
Pieter Fokko van Loo, Basav N Hangalapura, Soley Thordardottir, John D Gibbins, Henrike Veninga, Linda J A Hendriks, Arjen Kramer, Rob C Roovers, Marij Leenders, John de Kruif, Robert P Doornbos, Andres Sirulnik, Mark Throsby, Ton Logtenberg, Harry Dolstra, Alexander B H Bakker
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert opinion on biological therapy 19 (7) (2020)
Renée C G de Bruin, John P Veluchamy, Sinéad M Lougheed, Famke L Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G Stam, Zsolt Sebestyen, Jürgen Kuball, Carla F M Molthoff, Erik Hooijberg, Rob C Roovers, James P Di Santo, Paul M P van Bergen En Henegouwen, Henk M W Verheul, Tanja D de Gruijl, Hans J van der Vliet
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. Oncoimmunology 7 (1) (2017)